01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

More documents

Recommendations

Info

Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA (1997) Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 25, 320-325. Hansson JH, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton RP (1995) Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 11, 76-82. Harms JS, Splitter GA (1995) Intergeron-g inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 6, 1291-1297. Harrell RL, Rajanayagam S, Doanes AM, Guzman RJ, Hirschowitz EA, Crystal RG, Epstein SE, Finkel T (1997) Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 96, 621-627. Hart Sl (1994) Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem 269, 12468-12474. Hay JG, McElvaney NG, Herena J, Crystal RG (1995) Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 6, 1487-1496. Hay, R.T. (1985) Origin of adenovirus DNA replication. Role of the Nuclear Factor I binding site in vivo. J. Mol. Biol. 186, 129-136. Hayday, A.,C., Gillies, S.D., Saito, H., Wood, C., Wiman, K., Hayward, W.S. and Tonegawa, S. (1984) Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature 307, 334-340. Hayward WS, Neel BG, Astrin SM (1981) Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290, 475-480. Hazinski TA, Ladd PA, DeMatteo CA (1991) Localization and induced expression of fusion genes in the rat lung. Am J Respir Cell Mol Biol 4, 206-209. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B geneattenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3, 639-645. Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A (1992) A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70, 337-350. Hermeking H and Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265, 2091-2093. Hermonat PL, and Muzyczka N (1984) Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 81, 6466-6470. Hermonat PL, Quirk JG, Bishop BM, Han L (1997) The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett 407, 78-84. Boulikas: An overview on gene therapy 142 Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, Brisbay S, McDonnell TJ (1997) Bcl-2 suppresses apoptosis resulting from disruption of the NF-κB survival pathway. Exp Cell Res 237, 101-109. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, et al (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 316, 589-596. Herz J and Gerard RD (1993) Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 90, 2812-2816. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94, 5804-5809. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, and Cleveland JL (1995) E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 15, 6864-6874. Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS (1981) Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminasedeficient patients. J Clin Invest 68, 1387-1393. Hoeben RC (1998) Gene therapy for haemophilia. Gene Ther Mol Biol 1, 293-300. Hofland HEJ, Shephard L, Sullivan SM (1996) Formation of stable cationic lipid/DNA complexes for gene transfer. Proc Natl Acad Sci USA 93, 7305-7309. Hofmann C, Lehnert W, and Strauss M (1997) The baculovirus vector system for gene delivery into hepatocytes. Gene Ther Mol Biol 1, Hollenberg NK (1996) Genes, hypertension, and intermediate phenotypes. Curr Opin Cardiol 11, 457-463. Hollstein M, Sidransky D ,Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253, 49-53. Holt JT, Arteaga CB, Robertson D, Moses HL (1996) Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum Gene Ther 7, 1367- 1380. Horellou P, Mallet J (1997) Gene therapy for Parkinson's disease. Mol Neurobiol 15, 241-256. Horn NA, Meedi JA, Budahazi G, Marquet M (1995) Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials. Hum Gene Ther 6, 565-573. Horowitz JM, Yandell DW, Park S-H, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP (1989) Point mutational inactivation of the retinoblastoma antioncogene. Science 243, 937-940. Hu E, Kim JB, Sarraf P, and Spiegelman BM (1996) Inhibition in adipogenesis through MAP kinase-mediated phosphoryl;ation of PPARγ. Science 274, 2100-2103. Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, Lee EYHP, Lee W-H (1988) Suppression of
the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242, 1563-1566. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinaoma cells genetically modified to express cytosine deaminase. Cancer Res 53, 4619-4626. Huber BE, Austin EA, Richards CA, Davis ST, Good SS (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91, 8302-8306. Huber BE, Richards CA, Krenitsky TA (1991) Retroviralmediated gene therapy for the treatment of hepatocellular carcinaoma: An innovative approach for cancer therapy. Proc Natl Acad Sci USA 88, 8039-8043. Hunger, S.P., Ohyashiki, K., Toyama, K. and Cleary, M.L. (1992) Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 6, 1608-1620. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC (1997) Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 57, 4722-4726. Hupp TR, Meek DW, Midgley CA, and Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71, 875-886. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, Drowart A, Lozes E, Vandenbussche P, Van Vooren JP, Liu MA, Ulmer JB (1996) Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med 2, 893- 898. Hyde SC, Gill DR, Higgins CF, Trezise AEO, MacVinish LJ, Cuthbert AW, Ratcliff R, Evans MJ, Colledge WH (1993) Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362, 250-255. Iida A, Chen ST, Friedmann T, Yee JK (1996) Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J Virol 70, 6054-6059. Ikonen E, Aula P, Gron K, Tollersrud O, Halila R, Manninen T, Syvanen A-C, Pertonen L (1991) Spectrum of mutations in aspartylglucosaminuria. Proc Natl Acad Sci USA 88, 11222-11226. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, et al (1995) Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1, 541-545. Inouye RT, Du B, Boldt-Houle D, Ferrante A, Park IW, Hammer SM, Duan L, Groopman JE, Pomerantz RJ, Terwilliger EF (1997) Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adenoassociated virus vector. J Virol 71, 4071-4078. Gene Therapy and Molecular Biology Vol 1, page 143 143 Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, and Ewing CM (1994) Molecular biology of prostate cancer. Semin Oncol 21, 514-521. Isaacs WB, Carter BS, and Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51, 4716-4720. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J (1997) Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 272, 10050- 10057. Ishizaki J, Nevins JR, Sullenger BA (1996) Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat Med 2, 1386-1389. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF (1996b) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-374. Isner JM, Walsh K, Rosenfield K, Schainfeld R, Asahara T, Hogan K, and Pieczek A (1996a) Clinical protocol. Arterial gene therapy for restenosis. Hum Gene Ther 7, 989-1011. Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB (1997) Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res 57, 2937- 2942. Jaaskelainen I, Monkkonen J, Urtti A (1994) Oligonucleotidecationic liposome interactions. A physicochemical study. Biochim Biophys Acta 1195, 115-123. Jaffee EM, Pardoll DM (1997) Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 12, 143-153. Janicek MF, Sevin BU, Nguyen HN, Averette HE (1995) Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines. Gynecol Oncol 59, 87-92. Jänicke RU, Walker PA, Lin XY, and Porter AG (1996) Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15, 6969-6978. Jendraschak E and Sage EH (1996) Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 7, 139-146. Jessberger R, Heuss D, Doerfler W (1989) Recombination in hamster cell nuclear extracts between adenovirus type 12 DNA and two hamster preinsertion sequences. EMBO J 8, 869-878. Ji W and St CW (1997) Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J Viral Hepat 4, 167-173. Jiao S, Gurevich V, and Wolff JA (1993) Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 362, 450-453. Jin L, Zhang JJ, Chao L, Chao J (1997) Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 8, 1753-1761. Johnson P, Chung S, and Benchimol S (1993) Growth suppression of Friend virus-transformed erythroleukemia
Page 1 and 2:
Gene Ther Mol Biol Vol 1, 1-172. Ma
Page 3 and 4:
I. Introduction Monumental progress
Page 5 and 6:
The use of retroviral vectors in hu
Page 7 and 8:
displaying the cleavable EGF domain
Page 9 and 10:
molecules in the nucleus (Lowe and
Page 11 and 12:
sensitive mutations which allow pro
Page 13 and 14:
processed as described in panel A s
Page 15 and 16:
On the contrary, the payload capaci
Page 17 and 18:
in K562 human erythroleukemia cells
Page 19 and 20:
defective HSV virus (DeLuca and Sch
Page 21 and 22:
complex into the cytosol from the e
Page 23 and 24:
Gene Therapy and Molecular Biology
Page 25 and 26:
delivered by Sendai virus-liposome
Page 27 and 28:
plasmids with the cell surface, tra
Page 29 and 30:
infected by adenovirus alone; infec
Page 31 and 32:
Page 33 and 34:
B. Transcription factor binding sit
Page 35 and 36:
A closely related family of ubiquit
Page 37 and 38:
cells. I-CreI is a member of this c
Page 39 and 40:
Page 41 and 42:
C. Considerations of chromatin stru
Page 43 and 44:
Page 45 and 46:
A. The molecular basis of cancer im
Page 47 and 48:
fragments, or heat shock proteins c
Page 49 and 50:
ecombinant vaccinia virus expressin
Page 51 and 52:
HIV-1 envelope DNA construct develo
Page 53 and 54:
inding sites A GYYY oriented in opp
Page 55 and 56:
Page 57 and 58:
Prives, 1994). Whereas the wild-typ
Page 59 and 60:
mutant p53 (mutations on p53 are wi
Page 61 and 62:
master regulator of the cell cycle
Page 63 and 64:
Work from several groups has shown
Page 65 and 66:
chromatin condensation, drop in pH,
Page 67 and 68:
Figure 23. A pathway leading to the
Page 69 and 70:
Excessive necrotic death in cells o
Page 71 and 72:
implantation, and similar processes
Page 73 and 74:
normal cells in the surroundings. T
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
A bicistronic retroviral vector (Ha
Page 81 and 82:
C. Antisense ras gene transfer for
Page 83 and 84:
equal to 6.0 showed S1 hyperreactiv
Page 85 and 86:
protein (e.g. Smith et al, 1995; Fo
Page 87 and 88:
transduced primary mouse fibroblast
Page 89 and 90:
IL-1 - receptor antagonist protein
Page 91 and 92: p53 lung cancer retroviru s MHC cla
Page 93 and 94: Gene Therapy and Molecular Biology
Page 95 and 96: designed by immunization with porti
Page 97 and 98: Isolation of an RNA aptamer that ca
Page 99 and 100: induction of human apoE in neonate
Page 101 and 102: atrium in heart, endothelial cells
Page 103 and 104: which eliminated tumors in small an
Page 105 and 106: C. Transfer of other genes against
Page 109 and 110: significant reduction in neointima
Page 111 and 112: (Prehn et al, 1996); this implies a
Page 113 and 114: B. Approaches to gene therapy of RA
Page 115 and 116: of human immunoglobulin and antigen
Page 117 and 118: A. Etiology and mechanisms of destr
Page 121 and 122: However, CsA also inhibits the acti
Page 123 and 124: The peptide kinin, after binding to
Page 125 and 126: intake when administered to adrenal
Page 127 and 128: Introgen Therapeutics (Austin and H
Page 129 and 130: When a subfragment of only 513 bp o
Page 131 and 132: Armentano D, Zabner J, Sacks C, Soo
Page 133 and 134: Brady HJM, Miles CG, Pennington DJ,
Page 135 and 136: Chen J, Stickles RJ, Daichendt KA (
Page 137 and 138: Day ML, Wu S, Basler JW (1993) Pros
Page 139 and 140: Farmer G, Bargonetti J, Zhu H, Frie
Page 141: Giovannangeli C, Perrouault L, Escu
Page 145 and 146: integrate in a site-specific fashio
Page 147 and 148: Li R, Waga S, Hannon GJ, Beach D, S
Page 149 and 150: adiation-induced apoptosis in the g
Page 151 and 152: Nakaya T, Iwai S, Fujinaga K, Sato
Page 153 and 154: Polyak K, Xia Y, Zweier JL, Kinzler
Page 155 and 156: macrophages from simian immunodefic
Page 157 and 158: intimal hyperplasia in a rat caroti
Page 159 and 160: Trono D, Feinberg MB, Baltimore D (
Page 161 and 162: Wattiaux R, Jadot M, Warnier-Pirott
Page 163 and 164: similar to mammalian interleukin-1
Page 167 and 168: 24. Gene Marking /Infectious Diseas
Page 169 and 170: Drug 50. Gene Therapy /Phase I /Can
Page 171 and 172: 76. Gene Therapy /Phase I /Cancer /
Page 173 and 174: 99. Gene Therapy /Phase II /Cancer
Page 175 and 176: 120. Gene Therapy /Phase I /Monogen
Page 179 and 180: cancer not specified) /Immunotherap
show all

01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

Create successful ePaper yourself

Delete template?

Save as template?